Shares of cruise lines jump after CDC ends Covid-19 program

Shares of cruise lines jump after CDC ends Covid-19 program


NEW YORK, US – JULY 10: An aerial view of the cruise ship “Norwegian Joy” sails up the Hudson River in front of the skyline of Manhattan as the sun sets in New York City, United States on July 10, 2022.

Lokman Vural Elibol | Anadolu Agency | Getty Images

Shares of cruise lines including Carnival, Royal Caribbean and Norwegian rose Tuesday after the U.S. Center for Disease Control ended its Covid-19 program for cruise ships.

The CDC’s program for cruise ships, which became voluntary earlier this year, required all passengers to be tested, encouraged vaccinations for staff and passengers and outlined specific quarantine procedures in the event of an outbreak.

The CDC said it would still provide guidance for cruise ships handling of Covid-19 cases, but that companies can now use their own strategies to mitigate the spread on the virus. That means cruise lines can make their own policies regarding vaccination, testing, and quarantine requirements.

Carnival shares gained about 7% on Tuesday to close at $10.36, while Royal Caribbean shares gained almost 6% to $36.36 and Norwegian shares rose roughly 3.5% to $12.85.

The CDC’s change is expected to give cruise liners more flexibility, which could allow for more travelers on ships and lower costs for the industry.

“While we fully expect the cruise operators to continue to mandate passengers to be vaccinated before sailing,” wrote Steven M. Wieczynski, a Stifel analyst. “We believe today’s news will give the cruise operators more flexibility around the inclusion of younger individuals.”

A Royal Caribbean representative said the company is awaiting further guidance from the CDC before setting its own policies.

The cruise industry has been reeling since the pandemic began, and has more recently been working to recover business back toward pre-2020 levels.



Source

JPMorgan’s top biotech and pharma picks for the second half
Health

JPMorgan’s top biotech and pharma picks for the second half

Biopharmaceutical stocks’ underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm’s June outlook for biopharma that the sector’s poor performance can be traced back to concerns over President Donald Trump’s tariffs and his ” most favored nation ” executive order. […]

Read More
How twin sister triathletes doubled down on sports success to raise health-startup millions from investors
Health

How twin sister triathletes doubled down on sports success to raise health-startup millions from investors

During their last year of completing work for doctoral degrees in physiology, twin sisters Michal Mor and Merav Mor started to compete in Ironman triathlon races. The demand for peak fitness led them to the realize the importance of understanding personal metabolism, and the lack of data being collected on it through devices accessible to […]

Read More
It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech
Health

It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech

Two graduate students research chemical products in a laboratory in Xiwangzhuang Town, Zaozhuang City, Shandong province of China, on Dec. 26, 2023. Nurphoto | Nurphoto | Getty Images BEIJING — For all the attention on U.S.-China competition in artificial intelligence, new studies point to China’s rapid rise in biotechnology, especially for drug and agricultural development. […]

Read More